<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Magnesium sulphate for preventing preterm birth in threatened preterm labour - Crowther, CA - 2014 | Cochrane Library</title> <meta content="Magnesium sulphate for preventing preterm birth in threatened preterm labour - Crowther, CA - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001060.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Magnesium sulphate for preventing preterm birth in threatened preterm labour - Crowther, CA - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001060.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001060.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Magnesium sulphate for preventing preterm birth in threatened preterm labour" name="citation_title"/> <meta content="Caroline A Crowther" name="citation_author"/> <meta content="caroline.crowther@adelaide.edu.au" name="citation_author_email"/> <meta content="Julie Brown" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Christopher JD McKinlay" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Philippa Middleton" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD001060.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/08/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001060.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001060.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001060.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Obstetric Labor, Premature; Fetal Death; Magnesium Sulfate [adverse effects, *therapeutic use]; Premature Birth [*prevention &amp; control]; Randomized Controlled Trials as Topic; Tocolytic Agents [adverse effects, *therapeutic use]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001060.pub2&amp;doi=10.1002/14651858.CD001060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001060\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001060\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001060.pub2",title:"Magnesium sulphate for preventing preterm birth in threatened preterm labour",firstPublishedDate:"Aug 15, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001060.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001060.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001060.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001060.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001060.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001060.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001060.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001060.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6431 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001060.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/table_n/CD001060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/table_n/CD001060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Magnesium sulphate for preventing preterm birth in threatened preterm labour</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information#CD001060-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Caroline A Crowther</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information#CD001060-cr-0003">Julie Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information#CD001060-cr-0004">Christopher JD McKinlay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information#CD001060-cr-0005">Philippa Middleton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information/en#CD001060-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 August 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001060.pub2">https://doi.org/10.1002/14651858.CD001060.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001060-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001060-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001060-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001060-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001060-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001060-abs-0001" lang="en"> <section id="CD001060-sec-0001"> <h3 class="title" id="CD001060-sec-0001">Background</h3> <p>Magnesium sulphate has been used in some settings as a tocolytic agent to inhibit uterine activity in women in preterm labour with the aim of preventing preterm birth. </p> </section> <section id="CD001060-sec-0002"> <h3 class="title" id="CD001060-sec-0002">Objectives</h3> <p>To assess the effects of magnesium sulphate therapy given to women in threatened preterm labour with the aim of preventing preterm birth and its sequelae. </p> </section> <section id="CD001060-sec-0003"> <h3 class="title" id="CD001060-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (last searched 31 January 2014). </p> </section> <section id="CD001060-sec-0004"> <h3 class="title" id="CD001060-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of magnesium sulphate as the only tocolytic, administered by any route, compared with either placebo, no treatment or alternative tocolytic therapy (not magnesium sulphate) to women considered to be in preterm labour. </p> </section> <section id="CD001060-sec-0005"> <h3 class="title" id="CD001060-sec-0005">Data collection and analysis</h3> <p>At least two review authors assessed trial eligibility and risk of bias and undertook data extraction independently. </p> </section> <section id="CD001060-sec-0006"> <h3 class="title" id="CD001060-sec-0006">Main results</h3> <p>The 37 included trials (total of 3571 women and over 3600 babies) were generally of moderate to high risk of bias. Antenatal magnesium sulphate was compared with either placebo, no treatment, or a range of alternative tocolytic agents. </p> <p>For the primary outcome of giving birth within 48 hours after trial entry, no significant differences were seen between women who received magnesium sulphate and women who did not (whether placebo/no alternative tocolytic drug, betamimetics, calcium channel blockers, cox inhibitors, prostaglandin inhibitors, or human chorionic gonadotropin) (19 trials, 1913 women). Similarly for the primary outcome of serious infant outcome, there were no significant differences between the infants exposed to magnesium sulphate and those not (whether placebo/no alternative tocolytic drug, betamimetics, calcium channel blockers, cox inhibitors, prostaglandin inhibitors, human chorionic gonadotropin or various tocolytic drugs) (18 trials; 2187 babies). No trials reported the outcome of extremely preterm birth. In the seven trials that reported serious maternal outcomes, no events were recorded. </p> <p>In the group treated with magnesium sulphate compared with women receiving antenatal placebo or no alternative tocolytic drug, a borderline increased risk of total death (fetal, neonatal, infant) was seen (risk ratio (RR) 4.56, 95% confidence interval (CI) 1.00 to 20.86; two trials, 257 babies); none of the comparisons between magnesium sulphate and other classes of tocolytic drugs showed differences for this outcome (10 trials, 991 babies). The outcomes of neonatal and/or infant deaths and of fetal deaths did not show differences between magnesium sulphate and no magnesium sulphate, whether compared with placebo/no alternative tocolytic drug, or any specific class of tocolytic drug. For most of the other secondary outcomes, there were no significant differences between magnesium sulphate and the control groups for risk of preterm birth (except for a significantly lower risk with magnesium sulphate when compared with barbiturates in one trial of 65 women), gestational age at birth, interval between trial entry and birth, other neonatal morbidities, or neurodevelopmental outcomes. Duration of neonatal intensive care unit stay was significantly increased in the magnesium sulphate group compared with the calcium channel blocker group, but not when compared with cox inhibitors or prostaglandin inhibitors. No maternal deaths were reported in the four trials reporting this outcome. Significant differences between magnesium sulphate and controls were not seen for maternal adverse events severe enough to stop treatment, except for a significant benefit of magnesium sulphate compared with betamimetics in a single trial. </p> </section> <section id="CD001060-sec-0007"> <h3 class="title" id="CD001060-sec-0007">Authors' conclusions</h3> <p>Magnesium sulphate is ineffective at delaying birth or preventing preterm birth, has no apparent advantages for a range of neonatal and maternal outcomes as a tocolytic agent and its use for this indication may be associated with an increased risk of total fetal, neonatal or infant mortality (in contrast to its use in appropriate groups of women for maternal, fetal, neonatal and infant neuroprotection where beneficial effects have been demonstrated). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001060-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001060-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001060-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001060-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001060-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001060-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001060-abs-0006">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001060-abs-0004" lang="en"> <h3>Magnesium sulphate for preventing preterm birth in threatened preterm labour</h3> <p>Even short‐term postponement of birth when labour begins early (before 37 weeks) can help improve outcomes for babies, as the woman can take corticosteroid drugs to help develop the baby's lungs in a short time. Magnesium sulphate is one of the drugs that has been used to try to stop the uterus contracting in women who go into labour too soon. </p> <p>This review of 37 trials including 3571 women and their infants did not find that magnesium sulphate, given to women who go into labour too soon, prevented babies being born too soon or reduced the risks of the baby developing serious health problems. However, antenatal magnesium sulphate is effective in helping women who develop pre‐eclampsia (high blood pressure and protein in the urine) and for helping to protect babies' brains. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001060-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001060-sec-0119"></div> <h3 class="title" id="CD001060-sec-0120">Implications for practice</h3> <section id="CD001060-sec-0120"> <p>Evidence does not support the use of magnesium sulphate as an appropriate tocolytic agent to use for women in preterm labour. It is ineffective in delaying preterm birth and may be associated with a increased risk of death for the neonate (in contrast to beneficial effects of magnesium sulphate for maternal, fetal and infant neuroprotection in appropriate groups of women). Babies exposed to magnesium sulphate were not more likely to be admitted to the neonatal intensive care, but if admitted they were more likely to stay longer than those babies not exposed to magnesium sulphate. </p> </section> <h3 class="title" id="CD001060-sec-0121">Implications for research</h3> <section id="CD001060-sec-0121"> <p>Follow‐up of children whose mothers were enrolled in the already completed randomised trials is warranted. This will enable neurodevelopmental status during childhood to be determined. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001060-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001060-sec-0022"></div> <section id="CD001060-sec-0023"> <h3 class="title" id="CD001060-sec-0023">Description of the condition</h3> <p>Preterm birth remains the principal cause of early neonatal death (<a href="./references#CD001060-bbs2-0075" title="HowsonCP , KinneyMV , Lawn JE(editors) . Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012. ">March of Dimes 2012</a>). Infants born preterm (before 37 weeks' gestation) often suffer significant immediate morbidity and need lengthy stays in neonatal intensive care units (<a href="./references#CD001060-bbs2-0062" title="ClaasMJ , BruinseHW , van derHeide‐JalvingM , TermoteJ , deVriesLS . Changes in survival and neonatal morbidity in infants with a birthweight of 750g or less. Neonatology2010;98:278‐88. ">Claas 2010</a>; <a href="./references#CD001060-bbs2-0063" title="DarlowBA , MogridgeN , HarwoodLJ , Wynn‐WilliamsMB , AustinNC . Admisson of all gestations to a regional neonatal unit versus controls: Neonatal morbidity. Journal of Paediatrics and Child Health2009;45:181‐6. ">Darlow 2009</a>). Moreover, there is a significant risk of long‐term neurological morbidity in a proportion of the survivors (<a href="./references#CD001060-bbs2-0073" title="KugelmanA , BaderD , Lerner‐GevaL , BoykoV , LevitzkiO , RiskinA , et al. Poor outcomes at discharge among extremely premature infants: a national population based study. Archives of Pediatrics &amp; Adolescent Medicine2012;166(6):543‐50. ">Kugelman 2012</a>). The more preterm the baby the greater are the risks, especially when birth occurs before 32 weeks (<a href="./references#CD001060-bbs2-0061" title="BoyleE , PoulsenG , FieldD , KurinczukJ , WolkeD , AlfirevicZ , et al. Effects of gestational age at birth on health outcomes at 3 and 5 years of age: Population based cohort. BMJ2012;344:e896. ">Boyle 2012</a>). Parents are understandably worried and distressed when their baby is born preterm. Parents, health professionals and society share the burden of responsibility and costs, both personal and monetary, for preterm birth and its sequelae. The prevention of preterm birth therefore remains an important priority. </p> </section> <section id="CD001060-sec-0024"> <h3 class="title" id="CD001060-sec-0024">Description of the intervention</h3> <p>Tocolytic agents inhibit uterine contractions, and a variety have been used to inhibit uterine activity in women in preterm labour and so attempt to prevent preterm birth. Agents used include betamimetics, prostaglandin inhibitors, calcium channel blockers, ethanol, oxytocin receptor antagonists and magnesium sulphate. The ideal tocolytic agent should be easy to administer, inexpensive, without significant maternal, fetal or neonatal side effects, and effective at delaying preterm birth, at least long enough to permit the use of antenatal corticosteroids (<a href="./references#CD001060-bbs2-0068" title="HaasD , ImperialeT , KirkpatrickP , KleinR , ZollingerT , GowchowskiA . Tocolytic therapy. A meta‐analysis and decision analysis. Obstetrics and Gynecology2009;113:585‐94. ">Haas 2009</a>; <a href="./references#CD001060-bbs2-0080" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>). </p> <p>There is considerable variation in the type of tocolytic agent used in different parts of the world. Magnesium sulphate has been widely used as a tocolytic in the United States of America (<a href="./references#CD001060-bbs2-0060" title="BesingerR , NiebylJ . The safety and efficacy of tocolytic agents for the treatment of preterm labour. Obstetrical and Gynecological Survey1990;45:415‐39. ">Besinger 1990</a>; <a href="./references#CD001060-bbs2-0067" title="GrimesDA , NandaK . Magnesium sulfate tocolysis: time to quit. Obstetrics and Gynecology2006;108(4):986‐9. ">Grimes 2006</a>), although there have been reports of an increase in infant mortality (<a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>) and admission to neonatal intensive care (<a href="./references#CD001060-bbs2-0066" title="GreenbergM , PennA , ThomasL , El‐SayedY , CaugheyA , LyellD . Neonatal medical admission in a term and late preterm cohort exposed to magnesium sulphate. American Journal of Obstetrics and Gynecology2011;204(515):e1‐7. ">Greenberg 2011</a>) with a suggestion that there is a dose‐response relationship (<a href="./references#CD001060-bbs2-0066" title="GreenbergM , PennA , ThomasL , El‐SayedY , CaugheyA , LyellD . Neonatal medical admission in a term and late preterm cohort exposed to magnesium sulphate. American Journal of Obstetrics and Gynecology2011;204(515):e1‐7. ">Greenberg 2011</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>). In 2013 the US Food and Drug Administration advised against the use of antenatal magnesium sulphate for more than five to seven days when used to try to stop preterm labour, due to concerns about fetal and neonatal bone development; this led to the American College of Obstetricians and Gynecologists issuing a committee opinion supporting short‐term but not long‐term use (<a href="./references#CD001060-bbs2-0059" title="American College of Obstetrics and Gynecology. Magnesium sulfate use in obstetrics: committee opinion. Obstetrics &amp; Gynecology2013;122(3):727‐8. ">ACOG 2013</a>). </p> </section> <section id="CD001060-sec-0025"> <h3 class="title" id="CD001060-sec-0025">How the intervention might work</h3> <p>Magnesium sulphate was described as having an effect on uterine contractility by increasing the duration of labour in the late 1950s (<a href="./references#CD001060-bbs2-0070" title="HallD , McGaugheryHJr , CoreyE , ThorntonW . The effects of magnesium therapy on the duration of labour. American Journal of Obstetrics and Gynecology1959;78:27‐32. ">Hall 1959</a>). The exact mechanism of magnesium sulphate as a tocolytic agent is only partially understood. Magnesium decreases the frequency of depolarisation of smooth muscle, by modulating calcium uptake, binding and distribution in smooth muscle cells. The net result is inhibition of uterine contractions. Magnesium sulphate is essential for cellular health including glycolysis, oxidative phosphorylation, protein synthesis and plasma membrane integrity (<a href="./references#CD001060-bbs2-0077" title="McIntoshT , VinkR , YamakamiI , FadenA . Magnesium protects against neurological deficit after brain injury. Brain Research1989;482:252‐60. ">McIntosh 1989</a>; <a href="./references#CD001060-bbs2-0078" title="MildvanAS . Role of magnesium and other divalent cations in ATP‐utilizing enzymes. Magnesium1987;6(1):28‐33. ">Mildvan 1987</a>). </p> <p>Magnesium sulphate, by its peripheral vasodilator effects when infused intravenously, produces flushing, sweating, and a sensation of warmth. Reported maternal side effects relate to dosage and speed of infusion and include nausea, vomiting, headache, palpitations and rarely, pulmonary oedema. Administration to concentrations above the recommended therapeutic range can lead to respiratory depression, respiratory arrest and cardiac arrest (<a href="./references#CD001060-bbs2-0076" title="McDonnellNJ . Cardiopulmonary arrest in pregnancy: two case reports of successful outcomes in association with perimortem caesarian delivery. British Journal of Anaesthesia2009;103(3):406‐9. ">McDonnell 2009</a>). For the neonate, hypermagnesaemia can lead to hyporeflexia, poor sucking, and, rarely, respiratory depression needing mechanical ventilation (<a href="./references#CD001060-bbs2-0074" title="LipsitzPJ . The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics1971;47:501‐9. ">Lipsitz 1971</a>). </p> </section> <section id="CD001060-sec-0026"> <h3 class="title" id="CD001060-sec-0026">Why it is important to do this review</h3> <p>The previous version of this review concluded that magnesium sulphate was ineffective at delaying birth or preventing preterm birth and that its use was associated with an increased risk of infant mortality. Despite this evidence, using magnesium sulphate for tocolysis has remained a common practice in the USA in particular (<a href="./references#CD001060-bbs2-0067" title="GrimesDA , NandaK . Magnesium sulfate tocolysis: time to quit. Obstetrics and Gynecology2006;108(4):986‐9. ">Grimes 2006</a>). It is therefore important to integrate evidence that has become available since the last update in order to see the impact on the review's previous conclusions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001060-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001060-sec-0027"></div> <p>To assess the effects of magnesium sulphate therapy given to women in threatened preterm labour with the primary aim of preventing preterm birth and its sequelae. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001060-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001060-sec-0028"></div> <section id="CD001060-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001060-sec-0030"> <h4 class="title">Types of studies</h4> <p>All published, unpublished and ongoing randomised trials that compared outcomes for women in threatened preterm labour given magnesium sulphate alone for tocolysis, with outcomes in controls, with or without placebo or alternative tocolytic drug therapy (not magnesium sulphate), reported as papers or abstracts. Quasi‐randomised trials were included. </p> </section> <section id="CD001060-sec-0031"> <h4 class="title">Types of participants</h4> <p>Women considered to be in preterm labour given magnesium sulphate to reduce their risk of preterm birth. </p> </section> <section id="CD001060-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Magnesium sulphate as the only tocolytic, administered intravenously or orally, compared with either placebo, no placebo or alternative tocolytic therapy. Trials where magnesium sulphate was used as the primary tocolytic with an adjuvant tocolytic used in the case of failure, were included. Trials where the primary tocolytic was not magnesium sulphate but where magnesium sulphate was used as an adjuvant after treatment failure were excluded. Trials that assessed the use of magnesium sulphate as maintenance therapy after preterm labour were not included as they are covered in a separate review (<a href="./references#CD001060-bbs2-0071" title="HanS , CrowtherCA , MooreV . Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD000940.pub3] ">Han 2013</a>). </p> </section> <section id="CD001060-sec-0033"> <h4 class="title">Types of outcome measures</h4> <p>Clinically relevant outcomes for trials of tocolysis for inhibiting preterm labour have been prespecified following consultation with the editors and authors of the individual reviews. </p> <p>Consensus was reached on a set of ‘core’ outcomes, which are highlighted below. These will be included in all tocolysis reviews. In addition to these core outcomes, individual teams may include other outcomes as necessary. </p> <section id="CD001060-sec-0034"> <h5 class="title">Primary outcomes</h5> <p>Primary outcomes were chosen to be most representative of the clinically important measures of effectiveness and complications. Serious outcomes for the women and their infants are composite endpoints. All these events individually were expected to be rare and a modest change in their incidence more likely to be detected by using composite outcomes. The incidence of individual components were explored in the secondary outcomes. </p> <p> <ol id="CD001060-list-0001"> <li> <p><b>Birth less than 48 hours after trial entry</b>. </p> </li> <li> <p>Extremely preterm birth (less than 28 weeks' gestation).</p> </li> <li> <p><b>Serious infant outcome</b> (defined as death or chronic lung disease [need for supplemental oxygen at 28 days of life or later], grade three or four intraventricular haemorrhage or periventricular leukomalacia, major neurosensory disability (defined as any of legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay/intellectual impairment [defined as developmental quotient (DQ) or intelligence quotient (IQ) less than two standard deviations below mean])). </p> </li> <li> <p><b>Serious maternal outcome</b> (defined as death, cardiac arrest, respiratory arrest, admission to intensive care unit). </p> </li> </ol> </p> </section> <section id="CD001060-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p>These include other measures of effectiveness, complications, satisfaction with care and health service use. </p> <section id="CD001060-sec-0036"> <h6 class="title">For the infant/child</h6> <p> <ul id="CD001060-list-0002"> <li> <p><b>Fetal death, neonatal and infant death</b>; </p> </li> <li> <p>preterm birth (less than 37 weeks);</p> </li> <li> <p><b>very preterm birth (less than 34 weeks)</b>; </p> </li> <li> <p>gestational age at birth;</p> </li> <li> <p>birth less than 24 hours after trial entry;</p> </li> <li> <p>interval between trial entry and birth;</p> </li> <li> <p>Apgar score less than seven at five minutes;</p> </li> <li> <p>respiratory distress syndrome (RDS);</p> </li> <li> <p>use of assisted ventilation;</p> </li> <li> <p>air leak syndrome;</p> </li> <li> <p>chronic lung disease (need for supplemental oxygen at 28 days of life or later);</p> </li> <li> <p>intraventricular haemorrhage (IVH);</p> </li> <li> <p>grade three or four IVH;</p> </li> <li> <p>periventricular leukomalacia (PVL);</p> </li> <li> <p>necrotising enterocolitis (NEC);</p> </li> <li> <p>proven neonatal infection;</p> </li> <li> <p>cerebral palsy;</p> </li> <li> <p>blindness;</p> </li> <li> <p>deafness;</p> </li> <li> <p>developmental delay or intellectual impairment.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0037"> <h6 class="title">For the woman</h6> <p> <ul id="CD001060-list-0003"> <li> <p>Maternal death;</p> </li> <li> <p>cardiac arrest;</p> </li> <li> <p>respiratory arrest;</p> </li> <li> <p>admission to intensive care unit;</p> </li> <li> <p>discontinuation of therapy because of maternal adverse effects;</p> </li> <li> <p><b>adverse drug reaction</b>; </p> </li> <li> <p><b>other adverse effects of therapy</b> (including nausea, vomiting, respiratory depression, hypotension, tachycardia); </p> </li> <li> <p>women's satisfaction with the therapy;</p> </li> <li> <p>bleeding episodes (antepartum haemorrhage, postpartum haemorrhage, need for transfusion);</p> </li> <li> <p>mode of birth.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0038"> <h6 class="title">Use of health services</h6> <p> <ul id="CD001060-list-0004"> <li> <p>Length of postnatal stay;</p> </li> <li> <p>admission to neonatal intensive care and length of stay.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD001060-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group. </p> <section id="CD001060-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We contacted the Trials Search Co‐ordinator to search the Cochrane Pregnancy and Childbirth Group's Trials Register (last searched 31 January 2014). </p> <p>The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co‐ordinator and contains trials identified from: </p> <p> <ol id="CD001060-list-0005"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE;</p> </li> <li> <p>weekly searches of Embase;</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the ‘Specialized Register’ section within the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth Group</a>. </p> <p>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co‐ordinator searched the register for each review using the topic list rather than keywords. </p> <p>We did not apply any language restrictions.</p> </section> </section> <section id="CD001060-sec-0041"> <h3 class="title" id="CD001060-sec-0041">Data collection and analysis</h3> <p>For methods used in the previous version of this review, <i>see '</i><a href="./references#CD001060-bbs2-0081" title="CrowtherCA , HillerJE , DoyleLW . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001060] ">Crowther 2002</a>'. </p> <p>For this update, the following methods were used for assessing the reports that were identified as a result of the updated search. </p> <p>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group. </p> <section id="CD001060-sec-0042"> <h4 class="title">Selection of studies</h4> <p>At least two review authors independently assessed for inclusion all potential studies identified as a result of the search strategy. We resolved any disagreements through discussion. </p> </section> <section id="CD001060-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved any discrepancies through discussion. We entered data into Review Manager software (<a href="./references#CD001060-bbs2-0079" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and checked for accuracy. </p> <p>When information regarding any of the above was unclear, we attempted to contact authors of original reports to provide further details. </p> </section> <section id="CD001060-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001060-bbs2-0072" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration2011. ">Higgins 2011</a>). We resolved any disagreement by discussion. </p> <section id="CD001060-sec-0045"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>For each included study we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD001060-list-0006"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0046"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>For each included study we described the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001060-list-0007"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0047"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>For each included study we described the methods used, if any, to blind study participants and personnel from which intervention a participant received. We considered studies to be at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001060-list-0008"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0048"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>For each included study we described the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. </p> <p>We assessed the methods used to blind outcome assessment as:</p> <p> <ul id="CD001060-list-0009"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0049"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>For each included study, we described the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusions where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, we re‐included missing data in the analyses which we undertook. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001060-list-0010"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0050"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>For each included study we investigated the possibility of selective outcome reporting bias and described what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001060-list-0011"> <li> <p>low risk of bias (where it is clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001060-sec-0051"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> </section> <section id="CD001060-sec-0052"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Handbook</i> (<a href="http://archie.cochrane.org/sections/documents/view?version=z1212181516253162684622876719716%26format=REVMAN_GRAPHS#REF-Higgins-2011" target="_blank">Higgins 2011</a>). With reference to (1) to (6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="http://archie.cochrane.org/sections/documents/view?version=z1212181516253162684622876719716%26format=REVMAN_GRAPHS#SENSITIVITY_ANALYSIS" target="_blank">Sensitivity analysis</a>. </p> </section> </section> <section id="CD001060-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data we used the numbers of events in the control and intervention groups of each study to calculate risk ratios (RRs) with 95% confidence intervals. For continuous data we calculated the mean difference (MDs) between treatment groups where outcomes were measured in the same way. Standardised mean differences would have been used if the outcomes from trials were the same but different methods had been used to collect the data. We reported 95% confidence intervals for all outcomes. </p> </section> <section id="CD001060-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>There were no major unit of analysis issues. Several trials had unit of analysis issues with reporting of interventions used or multiple births, which meant that not all of the outcome data could be included in the meta‐analysis (<a href="./references#CD001060-bbs2-0025" title="ParillaBV , TamuraRK , CohenLS , ClarkE . Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology1997;176(6):1166‐9. ">Parilla 1997</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>). </p> </section> <section id="CD001060-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>Levels of attrition were noted. For all of the outcomes, we carried out analyses using an intention‐to‐treat basis, where possible. All participants were analysed, where possible in the treatment group to which they were randomised, regardless of the actual treatment received. The denominator for each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD001060-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. This was done by assessing statistical heterogeneity using the Tau², Chi² and I² statistics. An I² measurement greater than 30% was taken to indicate substantial heterogeneity (<a href="./references#CD001060-bbs2-0072" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration2011. ">Higgins 2011</a>), and either a Tau² greater than zero, or a low P value (less than 0.10) in the Chi² test for heterogeneity. Where substantial heterogeneity was detected, we explored possible explanations in sensitivity/subgroup analyses. Statistical heterogeneity was taken into account when interpreting the results, especially where there was any variation in the direction of effect. </p> </section> <section id="CD001060-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. Some types of reporting bias (e.g. publication bias, multiple publication bias, language bias etc) reduce the likelihood that all studies eligible for a review will be retrieved. If all eligible studies are not retrieved, the review may be biased. We conducted a comprehensive search for eligible studies and were alert for duplication of data. When there were 10 or more studies in analyses, we used funnel plots to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD001060-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD001060-bbs2-0079" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used a random‐effects meta‐analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary was treated as the average range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not meaningful, we did not combine trials. </p> <p>Where we used random‐effects analysis, the results were presented as the average treatment effect with 95% confidence intervals, and estimates of I². </p> </section> <section id="CD001060-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses to examine separately the primary outcomes, and fetal, neonatal and infant mortality, for women exposed to magnesium sulphate compared with no treatment or placebo and women given magnesium sulphate compared with type of alternative tocolytic therapy (such as betamimetics, prostaglandin inhibitors, calcium channel blockers, nitric oxide donors and sedatives). </p> <p>Further analyses were planned to assess the primary outcomes, and fetal, neonatal and infant mortality, by dose of magnesium sulphate used. This was achieved by comparing trials with a magnesium maintenance protocol that recommended magnesium sulphate infusion rates of up to 2 g/hour with trials with a magnesium maintenance protocol of more than 2 g/hour. </p> <p>We conducted subgroup interaction tests.</p> </section> <section id="CD001060-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted a sensitivity analysis by looking at the primary outcomes, and fetal, neonatal and infant mortality, only in those trials that demonstrated low risk of bias for allocation concealment. </p> <p>We also conducted a sensitivity analysis restricted to trials that reported if it was possible for women to have been switched to an alternative drug or treatment. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001060-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001060-sec-0061"></div> <section id="CD001060-sec-0062"> <h3 class="title">Description of studies</h3> <p>Also see <a href="./references#CD001060-sec-0133" title="">Characteristics of included studies</a> table. </p> <section id="CD001060-sec-0063"> <h4 class="title">Results of the search</h4> <p>Fifty‐four trials of magnesium sulphate in threatened preterm labour have been identified.</p> <p>Thirty‐seven (with a total of 3571 women) of these 54 trials met our inclusion criteria (<a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0007" title="ClavinDK , BayhiDA , NolanTE , RigbyFB , CorkRC , MillerJM . Comparison of intravenous magnesium sulfate and nitroglycerin for preterm labour: preliminary data [abstract]. American Journal of Obsterics and Gynecology1996;174(1 Pt 2):307. ">Clavin 1996</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0015" title="HollanderDI , NageyDA , PupkinMJ . Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. American Journal of Obstetrics and Gynecology1987;156:631‐7. ">Hollander 1987</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0022" title="MillerJM , KeaneMWD , HorgerEO . A comparison of magnesium sulfate and terbutaline for the arrest of premature labor. International Journal of Gynecology and Obstetrics1984;22:117‐23. MillerJM , KeaneMWD , HorgerEO . Comparison of magnesium sulfate and terbutaline for the arrest of premature labor. Journal of Reproductive Medicine1982;27(6):348‐51. ">Miller 1982</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0025" title="ParillaBV , TamuraRK , CohenLS , ClarkE . Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology1997;176(6):1166‐9. ">Parilla 1997</a>; <a href="./references#CD001060-bbs2-0026" title="ParsonsMT , OwensCA , SpellacyWN . Thermic effects of tocolytic agents: decreased temperature with magnesium sulfate. Obstetrics and Gynecology1987;69:88‐90. ">Parsons 1987</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>; <a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a>; <a href="./references#CD001060-bbs2-0030" title="SciscioneA , GormanR , SchlossmanP , ColmorgenG . A randomized prospective study of intravenous magnesium sulfate, ritodrine, and subcutaneous terbutaline as treatments for preterm labor. American Journal of Obstetrics and Gynecology1993;168:376 [SPO Abstract 281]. ">Sciscione 1993</a>; <a href="./references#CD001060-bbs2-0031" title="SteerCM , PetrieRH . A comparison of magnesium sulfate and alcohol for the prevention of premature labor. American Journal of Obstetrics and Gynecology1977;129:1‐4. ">Steer 1977</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>; <a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a>). </p> </section> <section id="CD001060-sec-0064"> <h4 class="title">Included studies</h4> <p>Three of the trials were conducted in China (<a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>; <a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a>), one in Mexico (<a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>), five in Iran (<a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>), one from Italy (<a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>), one from Turkey (<a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>), one from Thailand (<a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>) and the remainder in the United States of America. </p> <section id="CD001060-sec-0065"> <h5 class="title">Gestational age</h5> <p>The gestational age at trial entry varied between the trials.</p> <p> <ul id="CD001060-list-0012"> <li> <p>Women at less than 30 weeks' gestation (<a href="./references#CD001060-bbs2-0025" title="ParillaBV , TamuraRK , CohenLS , ClarkE . Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology1997;176(6):1166‐9. ">Parilla 1997</a>); </p> </li> <li> <p>women at less than 32 weeks' gestation (<a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a>); </p> </li> <li> <p>women at less than 34 weeks' gestation (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0026" title="ParsonsMT , OwensCA , SpellacyWN . Thermic effects of tocolytic agents: decreased temperature with magnesium sulfate. Obstetrics and Gynecology1987;69:88‐90. ">Parsons 1987</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>); </p> </li> <li> <p>women at less than 35 weeks' gestation (<a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>; <a href="./references#CD001060-bbs2-0015" title="HollanderDI , NageyDA , PupkinMJ . Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. American Journal of Obstetrics and Gynecology1987;156:631‐7. ">Hollander 1987</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>); </p> </li> <li> <p>women at less than 36 weeks' gestation (<a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>; <a href="./references#CD001060-bbs2-0030" title="SciscioneA , GormanR , SchlossmanP , ColmorgenG . A randomized prospective study of intravenous magnesium sulfate, ritodrine, and subcutaneous terbutaline as treatments for preterm labor. American Journal of Obstetrics and Gynecology1993;168:376 [SPO Abstract 281]. ">Sciscione 1993</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>; <a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a>). </p> </li> </ul> </p> <p>The remainder included women at greater gestational ages up to 37 weeks. The gestation of women was not reported by <a href="./references#CD001060-bbs2-0007" title="ClavinDK , BayhiDA , NolanTE , RigbyFB , CorkRC , MillerJM . Comparison of intravenous magnesium sulfate and nitroglycerin for preterm labour: preliminary data [abstract]. American Journal of Obsterics and Gynecology1996;174(1 Pt 2):307. ">Clavin 1996</a> or <a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>. </p> </section> <section id="CD001060-sec-0066"> <h5 class="title">Loading dose</h5> <p>The protocol for the amount of magnesium sulphate to be used varied. The following loading doses of magnesium sulphate were reported: </p> <p> <ul id="CD001060-list-0013"> <li> <p>4 g/hour was used in 21 trials (<a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0015" title="HollanderDI , NageyDA , PupkinMJ . Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. American Journal of Obstetrics and Gynecology1987;156:631‐7. ">Hollander 1987</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0022" title="MillerJM , KeaneMWD , HorgerEO . A comparison of magnesium sulfate and terbutaline for the arrest of premature labor. International Journal of Gynecology and Obstetrics1984;22:117‐23. MillerJM , KeaneMWD , HorgerEO . Comparison of magnesium sulfate and terbutaline for the arrest of premature labor. Journal of Reproductive Medicine1982;27(6):348‐51. ">Miller 1982</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>; <a href="./references#CD001060-bbs2-0026" title="ParsonsMT , OwensCA , SpellacyWN . Thermic effects of tocolytic agents: decreased temperature with magnesium sulfate. Obstetrics and Gynecology1987;69:88‐90. ">Parsons 1987</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>; <a href="./references#CD001060-bbs2-0031" title="SteerCM , PetrieRH . A comparison of magnesium sulfate and alcohol for the prevention of premature labor. American Journal of Obstetrics and Gynecology1977;129:1‐4. ">Steer 1977</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>); </p> </li> <li> <p>4.5 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>); </p> </li> <li> <p>2.5 g/hour to 5 g/hour used in one trial (<a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>); </p> </li> <li> <p>5 g/hour was used in two trials (<a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a>); </p> </li> <li> <p>6 g/hour was used in seven trials (<a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a>); </p> </li> <li> <p>4 to 6 g/hour was used in two trials (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>); </p> </li> <li> <p>4 to 8 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0025" title="ParillaBV , TamuraRK , CohenLS , ClarkE . Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology1997;176(6):1166‐9. ">Parilla 1997</a>). </p> </li> </ul> </p> <p>Two trials did not state the dose used (<a href="./references#CD001060-bbs2-0007" title="ClavinDK , BayhiDA , NolanTE , RigbyFB , CorkRC , MillerJM . Comparison of intravenous magnesium sulfate and nitroglycerin for preterm labour: preliminary data [abstract]. American Journal of Obsterics and Gynecology1996;174(1 Pt 2):307. ">Clavin 1996</a>; <a href="./references#CD001060-bbs2-0030" title="SciscioneA , GormanR , SchlossmanP , ColmorgenG . A randomized prospective study of intravenous magnesium sulfate, ritodrine, and subcutaneous terbutaline as treatments for preterm labor. American Journal of Obstetrics and Gynecology1993;168:376 [SPO Abstract 281]. ">Sciscione 1993</a>). </p> </section> <section id="CD001060-sec-0067"> <h5 class="title">Maintenance dose</h5> <p>The protocol for the amount of magnesium sulphate used for maintenance varied between 1.5 to 6 g/hour in the trials. The following doses were reported for magnesium sulphate maintenance </p> <section id="CD001060-sec-0068"> <h6 class="title">2 g or less (14 trials)</h6> <p> <ul id="CD001060-list-0014"> <li> <p>1 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>); </p> </li> <li> <p>1.5 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a>); </p> </li> <li> <p>1.5 to 2 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>); </p> </li> <li> <p>2 g/hour was used in 11 trials (<a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0022" title="MillerJM , KeaneMWD , HorgerEO . A comparison of magnesium sulfate and terbutaline for the arrest of premature labor. International Journal of Gynecology and Obstetrics1984;22:117‐23. MillerJM , KeaneMWD , HorgerEO . Comparison of magnesium sulfate and terbutaline for the arrest of premature labor. Journal of Reproductive Medicine1982;27(6):348‐51. ">Miller 1982</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>; <a href="./references#CD001060-bbs2-0031" title="SteerCM , PetrieRH . A comparison of magnesium sulfate and alcohol for the prevention of premature labor. American Journal of Obstetrics and Gynecology1977;129:1‐4. ">Steer 1977</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0069"> <h6 class="title">More than 2 g (21 trials)</h6> <p> <ul id="CD001060-list-0015"> <li> <p>1.5 to 3.5 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>); </p> </li> <li> <p>2.5 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0025" title="ParillaBV , TamuraRK , CohenLS , ClarkE . Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology1997;176(6):1166‐9. ">Parilla 1997</a>); </p> </li> <li> <p>2 to 3 g/hour was used in four trials (<a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>; <a href="./references#CD001060-bbs2-0026" title="ParsonsMT , OwensCA , SpellacyWN . Thermic effects of tocolytic agents: decreased temperature with magnesium sulfate. Obstetrics and Gynecology1987;69:88‐90. ">Parsons 1987</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>); </p> </li> <li> <p>2 to 4 g/hour was used in 11 trials (<a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0015" title="HollanderDI , NageyDA , PupkinMJ . Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. American Journal of Obstetrics and Gynecology1987;156:631‐7. ">Hollander 1987</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>); </p> </li> <li> <p>2 to 5 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>); </p> </li> <li> <p>2 to 6 g/hour was used in one trial (<a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a>); </p> </li> <li> <p>4 to 6 g/hour was used in two trials (<a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>). </p> </li> </ul> </p> <p>Two trials did not specify the amount used (<a href="./references#CD001060-bbs2-0007" title="ClavinDK , BayhiDA , NolanTE , RigbyFB , CorkRC , MillerJM . Comparison of intravenous magnesium sulfate and nitroglycerin for preterm labour: preliminary data [abstract]. American Journal of Obsterics and Gynecology1996;174(1 Pt 2):307. ">Clavin 1996</a>; <a href="./references#CD001060-bbs2-0030" title="SciscioneA , GormanR , SchlossmanP , ColmorgenG . A randomized prospective study of intravenous magnesium sulfate, ritodrine, and subcutaneous terbutaline as treatments for preterm labor. American Journal of Obstetrics and Gynecology1993;168:376 [SPO Abstract 281]. ">Sciscione 1993</a>). </p> </section> </section> <section id="CD001060-sec-0070"> <h5 class="title">Comparisons</h5> <p>Magnesium was compared with nine other preparations or classes of drugs in the 37 included trials. </p> <section id="CD001060-sec-0071"> <h6 class="title">1) Magnesium versus no other tocolytic drugs</h6> <p> <ul id="CD001060-list-0016"> <li> <p><a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a> (saline); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a> (dextrose); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a> (hydration, sedation); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a> (sedation). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0072"> <h6 class="title">2) Magnesium versus betamimetics</h6> <p> <ul id="CD001060-list-0017"> <li> <p><a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0022" title="MillerJM , KeaneMWD , HorgerEO . A comparison of magnesium sulfate and terbutaline for the arrest of premature labor. International Journal of Gynecology and Obstetrics1984;22:117‐23. MillerJM , KeaneMWD , HorgerEO . Comparison of magnesium sulfate and terbutaline for the arrest of premature labor. Journal of Reproductive Medicine1982;27(6):348‐51. ">Miller 1982</a>; <a href="./references#CD001060-bbs2-0026" title="ParsonsMT , OwensCA , SpellacyWN . Thermic effects of tocolytic agents: decreased temperature with magnesium sulfate. Obstetrics and Gynecology1987;69:88‐90. ">Parsons 1987</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a> (terbutaline); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0015" title="HollanderDI , NageyDA , PupkinMJ . Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. American Journal of Obstetrics and Gynecology1987;156:631‐7. ">Hollander 1987</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>; <a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a> (ritodrine); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0030" title="SciscioneA , GormanR , SchlossmanP , ColmorgenG . A randomized prospective study of intravenous magnesium sulfate, ritodrine, and subcutaneous terbutaline as treatments for preterm labor. American Journal of Obstetrics and Gynecology1993;168:376 [SPO Abstract 281]. ">Sciscione 1993</a> (ritodrine and/or terbutaline). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0073"> <h6 class="title">3) Magnesium versus calcium channel blockers</h6> <p> <ul id="CD001060-list-0018"> <li> <p><a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a> (nifedipine); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a> (nicardipine). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0074"> <h6 class="title">4) Magnesium versus cox inhibitors</h6> <p> <ul id="CD001060-list-0019"> <li> <p><a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a> (celecoxib); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a> (rofecoxib). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0075"> <h6 class="title">5) Magnesium versus prostaglandin inhibitors</h6> <p> <ul id="CD001060-list-0020"> <li> <p><a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0025" title="ParillaBV , TamuraRK , CohenLS , ClarkE . Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology1997;176(6):1166‐9. ">Parilla 1997</a> (indomethacin); </p> </li> <li> <p><a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a> (ketorolac). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0076"> <h6 class="title">6) Magnesium versus alcohol</h6> <p> <ul id="CD001060-list-0021"> <li> <p><a href="./references#CD001060-bbs2-0031" title="SteerCM , PetrieRH . A comparison of magnesium sulfate and alcohol for the prevention of premature labor. American Journal of Obstetrics and Gynecology1977;129:1‐4. ">Steer 1977</a> (alcohol; dextrose). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0077"> <h6 class="title">7) Magnesium versus human chorionic gonadotropin</h6> <p> <ul id="CD001060-list-0022"> <li> <p><a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>. </p> </li> </ul> </p> </section> <section id="CD001060-sec-0078"> <h6 class="title">8) Magnesium versus nitroglycerin</h6> <p> <ul id="CD001060-list-0023"> <li> <p><a href="./references#CD001060-bbs2-0007" title="ClavinDK , BayhiDA , NolanTE , RigbyFB , CorkRC , MillerJM . Comparison of intravenous magnesium sulfate and nitroglycerin for preterm labour: preliminary data [abstract]. American Journal of Obsterics and Gynecology1996;174(1 Pt 2):307. ">Clavin 1996</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>. </p> </li> </ul> </p> </section> <section id="CD001060-sec-0079"> <h6 class="title">9) Magnesium versus obstetrician's preference</h6> <p> <ul id="CD001060-list-0024"> <li> <p><a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>. </p> </li> </ul> </p> </section> </section> </section> <section id="CD001060-sec-0080"> <h4 class="title">Excluded studies</h4> <p>All of the 17 excluded trials were excluded because they did not meet the inclusion criteria for study design or comparison (<a href="./references#CD001060-bbs2-0038" title="BehradV , MoossavifarN , MojtahedzadenM , EsmalliH , MoghtadeiiP . A prospective, randomized, controlled trial of high and low doses of magnesium sulfate for acute tocolysis. Acta Medica Iranica2003;41(2):126‐31. ">Behrad 2003</a>; <a href="./references#CD001060-bbs2-0039" title="DiRenzoGC , MignosaM , GerliS , BurnelliL , LuziG , ClericiG , et al. The combined maternal administration of magnesium sulfate and aminophylline reduces intraventricular hemorrhage in very preterm neonates. American Journal of Obstetrics and Gynecology2005;192:433‐8. ">Di Renzo 2005</a>; <a href="./references#CD001060-bbs2-0046" title="KaraM , YilmazE , AvciI , ÖgeT . Comparison of nifedipine with magnesium sulphate plus terbutaline for the treatment of preterm labor. Journal of the Turkish Society of Obstetrics and Gynecology2009;6(4):250‐6. ">Kara 2009</a>; <a href="./references#CD001060-bbs2-0047" title="MittendorfR , PrydePG . An overview of the possible relationship between antenatal pharmacologic magnesium and cerebral palsy. Journal of Perinatal Medicine2000;28:286‐93. ">Mittendorf 2000</a>; <a href="./references#CD001060-bbs2-0048" title="OgburnPL , HansenCA , WilliamsPP , ButlerJC , JosephMS , JulianTM . Magnesium sulfate and B‐mimetic dual‐agent tocolysis in preterm labor after single‐agent failure. Journal of Reproductive Medicine1985;30(8):583‐7. ">Ogburn 1985</a>; <a href="./references#CD001060-bbs2-0049" title="PrydePG , BesingerRE , GianopoulosJG , MittendorfR . Adverse and beneficial effects of tocolytic therapy. Seminars in Perinatology2001;25:316‐40. ">Pryde 2001</a>; <a href="./references#CD001060-bbs2-0051" title="SogukC , TaoisizOL , MunganT . Low dose treatment protocol in magnesium sulfate tocolysis. International Journal of Gynecology and Obstetrics2004;86:37‐8. ">Soguk 2004</a>; <a href="./references#CD001060-bbs2-0052" title="TerroneDA , RinehartBK , KimmelES , MayWL , LarmonJE , MorrisonJC . A prospective, randomized, controlled trial of high and low maintenance doses of magnesium sulfate for acute tocolysis. American Journal of Obstetrics and Gynecology2000;182(6):1477‐82. ">Terrone 2000</a>; <a href="./references#CD001060-bbs2-0053" title="WischnikA , HettenbachA , SchmidtR , ZiegerW , HugG , MelchertF . The influence of magnesium sulphate on the fluid balance during tocolysis with the betamimetic agent fenoterol. Gynakologische Rundschau1989;29(2):188‐91. ">Wischnik 1989</a>; <a href="./references#CD001060-bbs2-0054" title="ZygmuntM , HeilmannL , BergC , WallwienerD , GrischkeE , MunstedtK , et al. Local and systemic tolerability of magnesium sulphate for tocolysis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;107(2):168‐75. ">Zygmunt 2003</a>), were not randomised (<a href="./references#CD001060-bbs2-0042" title="HerschelM , MittendorfR . Case report: Tocolytic magnesium sulfate toxicity and unexpected neonatal death. Journal of Perinatology2001;21:261‐3. ">Herschel 2001</a>; <a href="./references#CD001060-bbs2-0045" title="IedaK , SasakiJ , MizunoS , MimuraS , SuzukiC , MiyazakiT , et al. The clinical effects of maternally administered magnesium sulfate on the neonate. Journal of Perinatal Medicine1991;2:225S. ">Ieda 1991</a>; <a href="./references#CD001060-bbs2-0050" title="ScudieroR , KhoshnoodB , PrydePG , LeeKS , MittendorfR . Perinatal death and tocolytic magnesium sulfate. Obstetrics and Gynecology2000;96:178‐82. ">Scudiero 2000</a>), used magnesium as an adjuvant therapy (<a href="./references#CD001060-bbs2-0040" title="FergusonJE , HensleighPA , KredensterD . Adjunctive use of magnesium sulfate with ritodrine for preterm labour. American Journal of Obstetrics and Gynecology1984;148:166‐71. FergusonJE , HolbrookRH , StevensonDK , HensleighPA , KredentserD . Adjunctive magnesium sulfate infusion does not alter metabolic changes associated with ritodrine tocolysis. American Journal of Obstetrics and Gynecology1987;156:103‐7. ">Ferguson 1984</a>; <a href="./references#CD001060-bbs2-0041" title="HatjisCG , SwainM , NelsonLH , MeisPJ , ErnestJM . Efficacy of combined administration of magnesium sulfate and ritodrine in the treatment of premature labor. Obstetrics and Gynecology1987;69:317‐22. ">Hatjis 1987</a>), did not meet the criteria for included population (<a href="./references#CD001060-bbs2-0043" title="HowH , CookC , CookV , SpinnatoJ . Preterm premature rupture of membranes: aggressive tocolysis versus expectant management. American Journal of Obstetrics and Gynecology1996;174:306. HowHY , CookCR , CookVD , MilesDE , SpinnatoJA . Preterm premature rupture of membranes: aggressive tocolysis versus expectant management. Journal of Maternal‐Fetal Medicine1998;7:8‐12. ">How 1998</a>) or did not report on tocolysis (<a href="./references#CD001060-bbs2-0044" title="HowHY , ZafaranchiL , StellaC , RechtK , MaxwellR , SibaiB , et al. Magnesium sulfate (MGSO4) tocolysis versus no tocolysis in women with preterm labor between 32 0/7 and 34 6/7 weeks of gestation: a randomized controlled trial [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S6. HowHY , ZafaranchiL , StellaCL , RechtK , MaxwellRA , SibaiBM , et al. Tocolysis in women with preterm labor between 32 0/7 and 34 6/7 weeks of gestation: a randomized controlled pilot study. American Journal of Obstetrics and Gynecology2006;194:976‐81. ">How 2006</a>). </p> </section> </section> <section id="CD001060-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD001060-fig-0001">Figure 1</a> and <a href="#CD001060-fig-0002">Figure 2</a> illustrate the risk of bias of the included trials in this review. Overall, we judged the included trials to be of moderate to high risk of bias. </p> <div class="figure" id="CD001060-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001060-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001060-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001060-sec-0082"> <h4 class="title">Allocation</h4> <p>Adequate allocation concealment was reported in six trials (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>). </p> <p>Four trials were quasi‐randomised (<a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0015" title="HollanderDI , NageyDA , PupkinMJ . Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. American Journal of Obstetrics and Gynecology1987;156:631‐7. ">Hollander 1987</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0031" title="SteerCM , PetrieRH . A comparison of magnesium sulfate and alcohol for the prevention of premature labor. American Journal of Obstetrics and Gynecology1977;129:1‐4. ">Steer 1977</a>). </p> <p>The remaining 27 trials provided insufficient detail to make a judgement on the adequacy of allocation concealment. </p> <p>Reporting of methods of sequence generation was more common, with 15 trials reporting adequate methods such as computer‐generated random number tables. </p> </section> <section id="CD001060-sec-0083"> <h4 class="title">Blinding</h4> <p>Use of a placebo and/or adequate blinding of participants and study personnel was reported in only four trials (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>). For most of the remaining trials, blinding of participants and study personnel would not have been feasible due to interventions being administered by different routes, for example. </p> <p>Blinding of outcome assessors was mentioned in only one trial (<a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>), where some outcomes were reported to have been assessed in a blinded manner. None of the other 36 trials specifically mentioned blinded assessment of outcomes, although we judged that this may have been done in one trial (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>). </p> </section> <section id="CD001060-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>Most trials (n = 20) were judged to be at low risk of attrition bias. Only two trials (<a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>) reported high and/or imbalanced losses to follow‐up. For the 15 remaining trials, attrition bias was judged to be unclear. </p> </section> <section id="CD001060-sec-0085"> <h4 class="title">Selective reporting</h4> <p>Only 11 trials appeared to be free of selective reporting bias. The main reason for being judged to be at unclear (n = 19) or high (n = 7) risk of bias was lack of reporting of perinatal outcomes. Two of the seven trials judged to have a high selective reporting bias each reported a single outcome ‐ maternal temperature in <a href="./references#CD001060-bbs2-0026" title="ParsonsMT , OwensCA , SpellacyWN . Thermic effects of tocolytic agents: decreased temperature with magnesium sulfate. Obstetrics and Gynecology1987;69:88‐90. ">Parsons 1987</a> and doppler flow in <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>. </p> </section> <section id="CD001060-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <p>The majority of trials (n = 20) were judged to have unclear risk of other sources of bias for reasons including baseline imbalances and unit of analysis issues. </p> </section> </section> <section id="CD001060-sec-0087"> <h3 class="title" id="CD001060-sec-0087">Effects of interventions</h3> <section id="CD001060-sec-0088"> <h4 class="title">1. Magnesium sulphate group versus placebo/no treatment or other tocolytic agent (all included trials) </h4> <section id="CD001060-sec-0089"> <h5 class="title">Primary outcomes</h5> <section id="CD001060-sec-0090"> <h6 class="title">Primary outcomes for the infant</h6> <p>'Birth in less than 48 hours from treatment' was reported in 19 trials that included 1913 women (<a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>). No significant differences were seen for the risk of birth within 48 hours of treatment for women given magnesium sulphate compared with women who did not receive magnesium sulphate (whether placebo/no alternative tocolytic drug: average risk ratio (RR) 0.56, 95% confidence interval (CI) 0.27 to 1.14, three trials, 182 women, I² = 80%; betamimetics: average RR 1.09, 95% CI 0.72 to 1.65, seven trials, 503 women, I² = 0%; calcium channel blockers: average RR 1.19, 95% CI 0.86 to 1.65, five trials, 588 women, I² = 0%; cox inhibitors: average RR 1.08, 95% CI 0.91 to 1.27, two trials, 318 women, I² = 0%: prostaglandin inhibitors: average RR 0.93, 95% CI 0.71 to 1.22, two trials, 221 women, I² = 0%; or human chorionic gonadotropin (HCG): average RR 1.37, 95% CI 0.47 to 4.04, one trial, 101 women, I² = 0%) ‐ <a href="./references#CD001060-fig-0013" title="">Analysis 1.1</a>. Significant heterogeneity was noted for the comparison of magnesium sulphate with placebo/no alternative tocolytic drugs and so a random‐effects model was used. </p> <p>There were no data on extremely preterm birth (&lt; 28 weeks' gestation).</p> <p>'Serious infant outcome' was reported in 18 trials (<a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>; <a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>). No significant differences were evident for the risk of serious infant outcome for women who received magnesium sulphate compared with women who did not (whether placebo/no alternative tocolytic drug: RR 2.34, 95% CI 0.78 to 7.01, three trials, 284 infants; betamimetics: RR 0.92, 95% CI 0.20 to 4.12, five trials, 344 infants; calcium channel blockers: RR 1.02, 95% CI 0.37 to 2.83, five trials, 675 infants; cox inhibitors: RR 8.19, 95% CI 0.45 to 150.22, two trials, 314 infants: prostaglandin inhibitors: RR 0.77, 95% CI 0.27 to 2.21, three trials, 355 infants; or various tocolytic drugs: RR 2.47, 95% CI 0.69 to 8.81, one trial, 106 infants) ‐ <a href="./references#CD001060-fig-0015" title="">Analysis 1.3</a>. The composition of this outcome varied between trials ‐ the <a href="./references#CD001060-sec-0133" title="">Characteristics of included studies</a> table describes the composite outcome to be used for each trial. </p> </section> <section id="CD001060-sec-0091"> <h6 class="title">Primary outcomes for the mother</h6> <p>No serious maternal outcomes were reported in seven trials (n = 930 women ‐ <a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>) ‐ <a href="./references#CD001060-fig-0016" title="">Analysis 1.4</a>. </p> </section> </section> <section id="CD001060-sec-0092"> <h5 class="title">Secondary outcomes</h5> <section id="CD001060-sec-0093"> <h6 class="title">Secondary outcomes for the infant</h6> <p>For 'birth in less than 24 hours from treatment' data were reported in four trials (<a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>; <a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a>) that included 473 women. No difference was seen for the risk of birth within 24 hours of treatment for women given magnesium sulphate compared with no alternative tocolytic drug (RR 1.05, 95% CI 0.64 to 1.74, one trial, 156 women) ‐ <a href="./references#CD001060-fig-0014" title="">Analysis 1.2</a>. However, there was an increased risk for birth in less than 24 hours for women given magnesium sulphate compared with betamimetics (RR 4.39, 95% CI 1.75 to 11.05, two trials, 197 women), and a decreased risk for women given magnesium sulphate when compared with prostaglandin inhibitors (RR 0.56, 95% CI 0.37 to 0.84, one trial, 120 women). </p> <p>No benefit was seen for magnesium sulphate on the risk of preterm birth at less than 37 weeks for women given magnesium sulphate compared with betamimetics (average RR 1.03, 95% CI 0.77 to 1.39, six trials, 473 women, I² = 56%), calcium channel blockers (average 1.06, 95% CI 0.87 to 1.29, three trials, 362 women, I² = 0%) or prostaglandin inhibitors (average RR 1.83, 95% CI 0.58 to 5.81, one trial, 88 women). However, there was a decreased risk for women given magnesium sulphate when compared with no alternative tocolytic drug (average RR 0.62, 95% CI 0.46 to 0.83, one trial, 65 women) ‐ <a href="./references#CD001060-fig-0017" title="">Analysis 1.5</a>. Heterogeneity was noted for the comparison of magnesium sulphate with betamimetics drugs and so a random‐effects model was used. No benefit was seen for magnesium sulphate compared with calcium channel blockers on the risk of very preterm birth at less than 34 weeks (RR 0.89, 95% CI 0.55 to 1.45, two trials, 170 women) ‐ <a href="./references#CD001060-fig-0018" title="">Analysis 1.6</a>. </p> <p>No significant differences were seen for gestational age at birth for women who received magnesium sulphate compared with women who did not (whether placebo/no alternative tocolytic drug: average RR ‐0.50 weeks, 95% CI ‐1.85 to 0.85, three trials, 273 women, I² = 68%; betamimetics: average RR ‐0.36 weeks, 95% CI ‐1.61 to 0.89, three trials, 152 women, I² = 53%; calcium channel blockers: average RR ‐0.06 weeks, 95% CI ‐0.72 to 0.60, three trials, 439 women, I² = 1%; calcium channel blockers labour in first 48 hours: average RR ‐0.21 weeks, 95% CI ‐0.93 to 0.51, one trial, 53 women; calcium channel blockers labour in 2‐10 days: average RR ‐0.20 weeks, 95% CI ‐1.82 to 1.42, one trial, 12 women; cox inhibitors: average RR ‐0.17 weeks, 95% CI ‐0.95 to 0.61, two trials, 298 women, I² = 15%: or prostaglandin inhibitors: average RR ‐0.60 weeks, 95% CI ‐1.98 to 0.78, one trial, 150 women) ‐ <a href="./references#CD001060-fig-0019" title="">Analysis 1.7</a>. Heterogeneity was noted for the comparison of magnesium sulphate with no other tocolytics or betamimetic drugs and so a random‐effects model was used. </p> <p>Interval between trial entry and birth (days) was reported in six trials including 556 women. No significant differences were seen between groups in time from trial entry to birth (magnesium sulphate versus no other tocolytic drug: mean difference (MD) 0.23 days, 95% CI ‐3.83 to 4.29, three trials, 273 women, I² = 9%; magnesium sulphate versus betamimetics: MD ‐1.72 days, 95% CI ‐14.89 to 11.45, three trials, 182 women, I² = 89%; magnesium sulphate versus prostaglandin inhibitors: MD ‐0.20 days, 95% CI ‐5.06 to 4.66, one trial, 101 women) ‐ <a href="./references#CD001060-fig-0020" title="">Analysis 1.8</a>. Significant heterogeneity was noted for the comparison of magnesium sulphate with betamimetic drugs and so a random‐effects model was used. The data for the interval between trial entry and birth show the mean to be smaller than the standard deviation in some trials, suggesting skew in these data. Caution is therefore recommended in interpretation of these data. </p> <p>In the group treated with magnesium sulphate compared with babies receiving antenatal placebo or no alternative tocolytic drug, a borderline increased risk of total death (fetal, neonatal and infant) was seen (RR 4.56, 95% CI 1.00 to 20.86; two trials, 257 babies); none of the comparisons between magnesium sulphate and other classes of tocolytic drugs showed differences for this outcome (10 trials, 991 babies) ‐ <a href="./references#CD001060-fig-0021" title="">Analysis 1.9</a>. The outcomes of neonatal and/or infant deaths and of fetal deaths did not show differences between magnesium sulphate and no magnesium sulphate, whether compared with placebo/no alternative tocolytic drug, or any specific class of tocolytic drug ‐ <a href="./references#CD001060-fig-0023" title="">Analysis 1.11</a>. Two fetal deaths occurred in the magnesium sulphate group in one trial (<a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>) and there was one fetal death in the calcium channel blocker group in <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>. In the other 11 trials that reported on fetal deaths there were none ‐ <a href="./references#CD001060-fig-0022" title="">Analysis 1.10</a>. </p> <p>We investigated the effects of magnesium sulphate on other neonatal morbidities (<a href="./references#CD001060-fig-0024" title="">Analysis 1.12</a> to <a href="./references#CD001060-fig-0032" title="">Analysis 1.20</a>). In one trial of 90 infants, no significant difference was seen between magnesium and calcium channel blockers for Apgar less than seven at five minutes (RR 1.07, 95% CI 0.39 to 2.94) ‐ <a href="./references#CD001060-fig-0024" title="">Analysis 1.12</a>. No beneficial effect was seen for magnesium sulphate on the risk of other neonatal morbidity including risk of respiratory distress syndrome (<a href="./references#CD001060-fig-0025" title="">Analysis 1.13</a>), need for assisted ventilation (<a href="./references#CD001060-fig-0026" title="">Analysis 1.14</a>), chronic lung disease (<a href="./references#CD001060-fig-0027" title="">Analysis 1.15</a>), intraventricular haemorrhage (any) (<a href="./references#CD001060-fig-0028" title="">Analysis 1.16</a>), severe intraventricular haemorrhage (<a href="./references#CD001060-fig-0029" title="">Analysis 1.17</a>), periventricular leukomalacia (<a href="./references#CD001060-fig-0030" title="">Analysis 1.18</a>), necrotising enterocolitis (<a href="./references#CD001060-fig-0031" title="">Analysis 1.19</a>), or proven infection (<a href="./references#CD001060-fig-0032" title="">Analysis 1.20</a>). </p> <p>We examined the effects of magnesium sulphate on neurodevelopment, although minimal data were reported. Data on cerebral palsy at childhood follow‐up at 18 months corrected age were available from one trial only (<a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>). No significant reduction in the risk of cerebral palsy was reported (RR 0.13, 95% CI 0.01 to 2.51; 106 infants) ‐ <a href="./references#CD001060-fig-0033" title="">Analysis 1.21</a>. </p> </section> <section id="CD001060-sec-0094"> <h6 class="title">Secondary outcomes for the women</h6> <p>There was a lack of reporting of maternal outcomes. There were no maternal deaths in the four trials that reported this outcome (<a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>). No cardiac arrests were reported (<a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>). <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a> reported one respiratory arrest in the magnesium sulphate group (1/76) compared with no respiratory arrests in the control group (0/80). There were no admissions to intensive care in the single trial reporting this outcome (<a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>). <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a> reported significantly more maternal outcomes (a composite of shortness of breath, pulmonary oedema, hypotension and chest pain) in the women who were given magnesium (P = 0.03) compared with controls (20/92 versus 10/100, respectively). <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a> reported one case of pulmonary oedema in the magnesium sulphate group and one woman in the nifedipine group developed pleural effusion. </p> <p>Fourteen trials that included 1134 women reported on maternal adverse effects sufficient to discontinue treatment. No significant differences were seen for any of the comparisons of magnesium sulphate, except for magnesium sulphate compared with betamimetics, which favoured magnesium sulphate (average RR 0.14 95% CI 0.03 to 0.75, five trials, 398 women). Significant heterogeneity was noted for the comparison of magnesium sulphate with no other tocolytic drugs and so a random‐effects model was used (average RR 1.31, 95% CI 0.01 to 221.68, four trials, 302 women, I² = 85%) ‐ <a href="./references#CD001060-fig-0038" title="">Analysis 1.26</a>. </p> <p><a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a> reported only cessation of therapy due to adverse events or treatment failure; however, neither of these was recorded in the magnesium group. </p> <p>More women who had been treated with magnesium sulphate experienced nausea compared with calcium channel blockers (average RR 5.25, 95% CI 2.29 to 12.07, I² = 32%, one trial, 192 women), although no differences were observed between magnesium sulphate and other tocolytics ‐ <a href="./references#CD001060-fig-0039" title="">Analysis 1.27</a>. More women who had been treated with magnesium sulphate experienced vomiting or nausea and/or vomiting when compared with calcium channel blockers or HCG (RR 5.22, 95% CI 2.08 to 13.10 one trial, 192 women; RR 63.75, 95% CI 4.01 to 1013.51, one trial, 101 women), although again no differences were observed between magnesium sulphate and other tocolytics ‐ <a href="./references#CD001060-fig-0040" title="">Analysis 1.28</a> and <a href="./references#CD001060-fig-0041" title="">Analysis 1.29</a> respectively. </p> <p>Significantly fewer women in the magnesium sulphate groups experienced hypotension compared with nitroglycerin (RR 0.32, 95% CI 0.14 to 0.74, two trials of 64 women), although no differences were observed between magnesium sulphate and other tocolytics ‐ <a href="./references#CD001060-fig-0042" title="">Analysis 1.30</a>. No significant differences between groups were seen for tachycardia (<a href="./references#CD001060-fig-0043" title="">Analysis 1.31</a>) or in the rate of caesarean birth (<a href="./references#CD001060-fig-0044" title="">Analysis 1.32</a>). </p> <p>With regards to health service usage, no differences were seen between the magnesium sulphate and control groups for neonatal intensive care unit admission ‐ <a href="./references#CD001060-fig-0045" title="">Analysis 1.33</a>. Heterogeneity was noted for the comparison of magnesium sulphate with calcium channel blockers and so a random‐effects model was used. Evidence from two trials (<a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>) indicated a significant increase in length of neonatal intensive care unit stay in the group exposed to magnesium sulphate compared with calcium channel blockers (MD 4.55 days, 95% CI 0.96 to 8.15, 383 infants) ‐ <a href="./references#CD001060-fig-0046" title="">Analysis 1.34</a>. </p> <p>Data were available for many of the secondary outcomes, although little information was given for maternal outcomes and for use of health services. No outcome data were reported for: extremely preterm birth (less than 28 weeks), air leak syndrome, blindness, deafness, developmental delay/intellectual impairment, adverse drug reaction, respiratory depression, women's assessment of therapy/care, antepartum or postpartum haemorrhage, need for transfusion and length of postnatal stay. </p> </section> </section> </section> <section id="CD001060-sec-0095"> <h4 class="title">2. Magnesium sulphate for tocolysis (subgrouped by dose of magnesium sulphate)</h4> <p>To explore the possible effect of magnesium sulphate dosage on outcomes, the trials were subgrouped where possible according to the maintenance of magnesium sulphate recommended in the trial reports as: </p> <p> <ul id="CD001060-list-0025"> <li> <p>low dose (2 g/hour or less), 14 trials: <a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0022" title="MillerJM , KeaneMWD , HorgerEO . A comparison of magnesium sulfate and terbutaline for the arrest of premature labor. International Journal of Gynecology and Obstetrics1984;22:117‐23. MillerJM , KeaneMWD , HorgerEO . Comparison of magnesium sulfate and terbutaline for the arrest of premature labor. Journal of Reproductive Medicine1982;27(6):348‐51. ">Miller 1982</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>; <a href="./references#CD001060-bbs2-0031" title="SteerCM , PetrieRH . A comparison of magnesium sulfate and alcohol for the prevention of premature labor. American Journal of Obstetrics and Gynecology1977;129:1‐4. ">Steer 1977</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0035" title="WangH , ZengW , LiuH , OuY . A randomized controlled trial on the treatment of preterm labour with ritodrine hydrochloride and magnesium sulfate. West China University of Medical Sciences2000;31(4):515‐7. ">Wang 2000</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>; <a href="./references#CD001060-bbs2-0037" title="ZhuB , FuY . Treatment of preterm labor with ritodrine. Chung Hua Fu Chan Ko Tsa Chih1996;31(12):721‐3. ">Zhu 1996</a>); and </p> </li> <li> <p>higher dose (greater than 2 g/hour), 21 trials: <a href="./references#CD001060-bbs2-0002" title="ArmsonBA , SamuelsP , MillerF , VerbalisJ , MainEK . Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. American Journal of Obstetrics and Gynecology1992;167:758‐65. ">Armson 1992</a>; <a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0015" title="HollanderDI , NageyDA , PupkinMJ . Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. American Journal of Obstetrics and Gynecology1987;156:631‐7. ">Hollander 1987</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0025" title="ParillaBV , TamuraRK , CohenLS , ClarkE . Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology1997;176(6):1166‐9. ">Parilla 1997</a>; <a href="./references#CD001060-bbs2-0026" title="ParsonsMT , OwensCA , SpellacyWN . Thermic effects of tocolytic agents: decreased temperature with magnesium sulfate. Obstetrics and Gynecology1987;69:88‐90. ">Parsons 1987</a>; <a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>). </p> </li> </ul> </p> <section id="CD001060-sec-0096"> <h5 class="title">Primary outcomes</h5> <section id="CD001060-sec-0097"> <h6 class="title">Primary outcomes for the infant</h6> <section id="CD001060-sec-0098"> <p><b>Birth in less than 48 hours from treatment</b></p> <p>Nine trials contributed data to the low‐dose subgroup (≤ 2 g/hr) (<a href="./references#CD001060-bbs2-0001" title="AramayoFJF , MartinezFJ , RosalesCL . Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labour [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecologia y Obstetricia de Mexico1990;58:265‐9. ">Aramayo 1990</a>; <a href="./references#CD001060-bbs2-0003" title="AsgharniaM , SobhaniA , Omidvar‐JalaliZ . Comparison of Mg‐sulfate and indomethacin in management of preterm labor. Journal of Gorgan University of Medical Sciences2002;4(10):7‐12. ">Asgharnia 2002</a>; <a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0020" title="MaL . Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei1992;72(3):158‐61. ">Ma 1992</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>; <a href="./references#CD001060-bbs2-0034" title="TchilinguirianNG , NajemR , SullivanGB , CraparoFJ . The use of ritodrine and magnesium sulfate in the arrest of premature labor. International Journal of Gynaecology and Obstetrics1984;22:117‐23. ">Tchilinguirian 1984</a>; <a href="./references#CD001060-bbs2-0036" title="WilkinsIA , LynchL , MehalekKE , BerkowitzGS , BerkowitzRL . Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. American Journal of Obstetrics and Gynecology1988;159:685‐9. ">Wilkins 1988</a>) and 10 trials contributed to the higher‐dose subgroup (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0006" title="ChauAC , GabertHA , MillerJM . A prospective comparison of terbutaline and magnesium for tocolysis. Obstetrics and Gynecology1992;80:847‐51. ">Chau 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0014" title="HaghighiL . Prevention of preterm delivery: nifedipine or magnesium sulfate. International Journal of Gynecology and Obstetrics1999;66(3):297‐8. ">Haghighi 1999</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>; <a href="./references#CD001060-bbs2-0033" title="TaherianAA , DehdarP . Comparison of efficacy and safety of nifedipine versus magnesium sulfate in treatment of preterm labour. Journal of Research in Medical Sciences2007;12(3):136‐42. ">Taherian 2007</a>). Significant heterogeneity was found for the risk of birth within 48 hours of treatment for the low‐dose subgroup only (I² = 61%). No difference was seen for the risk of birth within 48 hours of treatment for women given 2 g/hour of magnesium sulphate or less (average RR 0.91, 95% CI 0.60 to 1.38, using a random‐effects model), or in women given more than 2 g/hour of magnesium sulphate (average RR 1.04, 95% CI 0.90 to 1.19, using a random‐effects model) compared with controls ‐ <a href="./references#CD001060-fig-0047" title="">Analysis 2.1</a>. The evidence indicates that neither a low dose nor a high dose of magnesium were effective in prolonging time to birth (with a nonsignificant subgroup interaction test of Chi² 0.35, I² = 0%, P = 0.55). </p> <p>No data were reported for extremely preterm birth (less than 28 weeks).</p> <p>Serious infant outcomes were reported in four trials of low‐dose maintenance magnesium sulphate (<a href="./references#CD001060-bbs2-0008" title="CottonDB , StrassnerHT , HillLM , SchifrinBS , PaulRH . Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. Journal of Reproductive Medicine1984;29:92‐7. ">Cotton 1984</a>; <a href="./references#CD001060-bbs2-0018" title="LorzadehN , KazemiradS , LorzadrhM , DehnoriA . A comparison of human chorionic gonadotropin with magnesium sulphate in inhibition of preterm labor. Journal of Medical Science2007;7(4):640‐4. ">Lorzadeh 2007</a>; <a href="./references#CD001060-bbs2-0027" title="PezzatiM , GianiT , GambiB , DaniC , BertiniG , BiagiottiR , et al. Influence of maternal magnesium sulphate and ritodrine treatment on cerebral blood flow velocity of the preterm newborn. Acta Obstetricia et Gynecologica Scandinavica2001;80:818‐23. ">Pezzati 2001</a>; <a href="./references#CD001060-bbs2-0028" title="ArdaS , SayinNC , SutN , VarolFG . The effect of tocolytic agents on maternal and fetal doppler flow patterns in women with preterm labor. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. SayinNC , ArdaS , VarolFG , SutN . The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152:50‐4. ">Sayin 2010</a>) and 14 trials of high dose (<a href="./references#CD001060-bbs2-0004" title="BeallMH , EdgarBW , PaulRM , Smith‐WallaceT . A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. American Journal of Obstetrics and Gynecology1985;153:854‐9. ">Beall 1985</a>; <a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0009" title="CoxSM , ShermanML , LevenoKJ . Randomized investigation of magnesium sulfate for prevention of preterm birth. American Journal of Obstetrics and Gynecology1990;163:767‐72. CoxSM , ShermanML , LevenoKJ . Single‐center randomized trial of magnesium sulfate for inhibition of uterine contractions in preterm labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23‐27; Houston, Texas, USA. 1990:39. ">Cox 1990</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0013" title="GlockJL , MoralesWJ . Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:960‐4. MoralesWJ , GlockJL . Efficacy and safety of nifedipine vs magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;168:375 [SPO Abstract 119]. ">Glock 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0017" title="LarmonJE , RossBS , MayWL , DickersonGA , FischerRG , MorrisonJC . Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. American Journal of Obstetrics and Gynecology1999;181:1432‐7. ">Larmon 1999</a>; <a href="./references#CD001060-bbs2-0019" title="LyellD , PennA , CaugheyA , KogutE , McLellanL , AdamsB , et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs. nifedipine tocolysis RCT. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S180‐S181. LyellD , PullenK , CampbellL , ChingS , BurrsD , ChitkaraU , et al. Magnesium sulfate versus nifedipine for acute tocolysis of preterm labor [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S18. LyellDJ , PullenK , CampbellL , ChingS , DruzinML , ChitkaraU , et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor ‐ a randomized controlled trial. Obstetrics and Gynecology2007;110(1):61‐7. ">Lyell 2007</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>; <a href="./references#CD001060-bbs2-0023" title="LeeK‐S , MittendorfR , BesingerR , GianopoulosJ , PrydeP . Mechanisms of mortality in the magnesium and neurologic endpoints trial (Magnet Trial): Papile grade III neonatal intraventricular hemorrhage (IVH). Pediatric Research2002;51(2 of 2):411A. LeeK‐S , MittendorfR , BesingerR , GianopoulusJ , PrydeP . Correlation between fetal‐fetal and maternal‐fetal ionized magnesium levels. Pediatric Research2002;51(2 of 2):314A. MittendorfR , BentzL , BorgM , RoizenN . Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S20. MittendorfR , BentzL , KohnJ , CovertR . Use of antenatal magnesium sulfate does not seem to prevent intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S34. MittendorfR , CovertR , BomanJ , KhoshnoodB , LeeK‐S , SeiglerM . Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet1997;350:1517‐8. MittendorfR , CovertR , ElinR , PrydePG , KhoshnoodB , LeeK . Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics and Gynecology2001;98:75‐8. MittendorfR , DambrosiaJ , DammannO , PrydeP , LeeK‐S , Ben‐AmiT , et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics2002;140:540‐6. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , KhoshnoodB , LeeK‐S , PrydeP , YousefzadehD . Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology2001;184(1):S188. MittendorfR , DambrosiaJ , PrydePG , LeeKS , GianopoulosJG , BesingerRE , et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology2002;186(6):1111‐8. MittendorfR , JaneczekS , MacmillanW , GianopoulosJ , BesingerR , KarlmanR , et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (MAGnet trial): fetal inflammatory response syndrome (FIRS). American Journal of Obstetrics and Gynecology2001;185(6 Suppl):S151. MittendorfR , KhoshmoodB , PrydeP , LeeK‐S , SriramS . Predicting neonatal serum ionized magnesium levels at delivery. Pediatric Research2001;49(2 of 2):407A. MittendorfR , KubanK , PrydePG , GianopoulosJG , YousefzadehD . Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology2005;25(2):101‐7. MittendorfR , PrydeP . Tocolytic magnesium sulfate: are the epidemiologic data reassuring?. American Journal of Obstetrics and Gynaecology1998;179(1):280. MittendorfR , PrydeP , KhoshnoodB , LeeK‐S . If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics and Gynecology1998;92(2):308‐11. MittendorfR , RoizenN , MoawadA , KhoshnoodB , LeeK‐S . Association between cerebral palsy and coagulase‐negative staphylococci. Lancet1999;354:1875‐6. MittendorfR , StratfordR , KhoshnoodB , LeeK‐S , PrydeP . Persistence of elevated serum magnesium levels in the neonate. American Journal of Obstetrics and Gynaecology2001;184(1):S50. ">Mittendorf 2002</a>; <a href="./references#CD001060-bbs2-0024" title="MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: A randomized study. JAMA1993;270(22):2676. MoralesWJ , MadhavH . Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. American Journal of Obstetrics and Gynecology1993;169:97‐102. MoralesWJ , MadhavH . Efficacy and safety of indomethacin vs magnesium sulfate in the management of preterm labor: A randomized study. American Journal of Obstetrics and Gynecology1991;164:280 [SPO Abstract 119]. ">Morales 1993</a>; <a href="./references#CD001060-bbs2-0029" title="SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEF , PerryKG , et al. Ketorolac is a safe and effective drug for acute tocolysis. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S7 [SPO Abstract 16]. SchorrSJ , AscarelliMH , RustOA , RossEL , CalfeeEL , PerryKG , et al. Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. Southern Medical Journal1998;91(11):1028‐31. ">Schorr 1997</a>; <a href="./references#CD001060-bbs2-0032" title="SurichamornP . The efficacy of terbutaline and magnesium sulfate in the management of preterm labor. Journal of the Medical Association of Thailand2001;84:98‐104. ">Surichamorn 2001</a>). There was no evidence of heterogeneity; or of a difference in serious infant outcomes between the low‐dose magnesium sulphate subgroup and the control group (RR 0.83, 95% CI 0.15 to 4.65); or for the higher‐dose magnesium group compared with the control group (RR 1.48, 95% CI 0.83 to 2.63), I² = 0%; 32/1014 compared with 30/1173, respectively). The subgroup interaction test was not significant (Chi² = 0.39, I² 0%, P = 0.53) ‐ <a href="./references#CD001060-fig-0048" title="">Analysis 2.2</a>. </p> </section> </section> <section id="CD001060-sec-0099"> <h6 class="title">Primary outcome for the women</h6> <p>Serious maternal outcomes were reported in seven trials (three in the low‐dose and four in the higher‐dose subgroup). No events were reported in any of these ‐ <a href="./references#CD001060-fig-0049" title="">Analysis 2.3</a>. </p> </section> <section id="CD001060-sec-0100"> <h6 class="title">Secondary outcomes (selected)</h6> <p>For total deaths (<a href="./references#CD001060-fig-0050" title="">Analysis 2.4</a>) and fetal deaths (<a href="./references#CD001060-fig-0051" title="">Analysis 2.5</a>), subgroup interaction tests could not be calculated as no deaths were reported in the low‐dose subgroup. For neonatal and/or infant deaths (<a href="./references#CD001060-fig-0052" title="">Analysis 2.6</a>), the subgroup interaction test was not significant (ChiI² = 0.93, I² = 0%, P = 0.33). </p> </section> </section> </section> <section id="CD001060-sec-0101"> <h4 class="title">3. Magnesium sulphate versus placebo/no treatment or other tocolytic agent ‐ sensitivity analysis (using trials at low risk of bias) </h4> <p>Six trials including 846 women were rated as low risk of bias for allocation concealment (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0010" title="El‐SayedYY , RileyET , HolbrookRH , CohenSE , ChitkaraU , DruzinML . Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labour. Obstetrics and Gynecology1999;93:79‐83. ">El‐Sayed 1999</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>). </p> <section id="CD001060-sec-0102"> <h5 class="title">Primary outcomes</h5> <section id="CD001060-sec-0103"> <h6 class="title">Primary outcomes for the infant</h6> <section id="CD001060-sec-0104"> <p><b>Birth in less than 48 hours from treatment</b></p> <p> <ul id="CD001060-list-0026"> <li> <p>Restricting the analysis to the three trials with adequate allocation concealment that reported this outcome (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>) made little material difference (RR 0.83, 95% CI 0.44 to 1.58). </p> </li> </ul> </p> </section> <section id="CD001060-sec-0105"> <p><b>Serious infant outcomes</b></p> <p> <ul id="CD001060-list-0027"> <li> <p>Restricting the analysis to the five trials with adequate allocation concealment (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>) again made little difference to the result (RR 1.21, 95% CI 0.52 to 2.80). </p> </li> </ul> </p> </section> </section> <section id="CD001060-sec-0106"> <h6 class="title">Primary outcomes for the mother</h6> <section id="CD001060-sec-0107"> <p><b>Serious maternal outcomes</b></p> <p> <ul id="CD001060-list-0028"> <li> <p>No serious maternal outcomes were reported in the two trials (<a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>) with adequate allocation concealment ‐ as was also the case for the other five trials. </p> </li> </ul> </p> </section> </section> </section> <section id="CD001060-sec-0108"> <h5 class="title">Secondary outcomes</h5> <section id="CD001060-sec-0109"> <h6 class="title">Fetal, neonatal and infant mortality</h6> <p> <ul id="CD001060-list-0029"> <li> <p>Restricting the analysis to the three trials with adequate allocation concealment (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>) reporting total fetal, neonatal and infant deaths maintained a non‐significant result (RR 0.41, 95% CI 0.02 to 9.91). Note that this analysis now contains only one death (as does the corresponding sensitivity analysis for fetal death). </p> </li> <li> <p>For neonatal and infant deaths, restricting the analysis to the five trials with adequate allocation concealment (<a href="./references#CD001060-bbs2-0005" title="BornaS , SaeidiFM . Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. Journal of Obstetrics and Gynaecology Research2007;33(5):631‐4. ">Borna 2007</a>; <a href="./references#CD001060-bbs2-0011" title="FloydRC , McLaughlinBN , MartinRW , RobertsWE , WiserWL , MorrisonJC . Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labor [abstract]. American Journal of Obstetrics and Gynecology1992;166:446 [SPO Abstract 662]. FloydRC , McLaughlinBN , PerryKG , MartinRW , SullivanCA , MorrisonJC . Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. Journal of Maternal‐Fetal Investigation1995;5:25‐9. ">Floyd 1992</a>; <a href="./references#CD001060-bbs2-0012" title="FoxMD , AllbertJR , McCaulJF , MartinRW , McLaughlinBN , MorrisonJC . Neonatal morbidity between 34 and 37 weeks' gestation. Journal of Perinatology1993;XIII:349‐63. FoxMD , McCaulJF , MartinRW , RobertsWE , McLaughlinB , MorrisonJC . Neonatal morbidity between 34‐37 weeks' gestation. American Journal of Obstetrics and Gynecology1992;166:360. ">Fox 1993</a>; <a href="./references#CD001060-bbs2-0016" title="KlauserCK , BrieryCM , KeiserSD , MartinRW , KosekMA , MorrisonJC . Effect of antenatal tocolysis on neonatal outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(12):2778‐81. KlauserCK , BrieryCM , MartinRW , LangstonL , MagannEF , MorrisonJC . A comparison of three tocolytics for preterm labor: a randomized clinical trial. Journal of Maternal‐Fetal and Neonatal Medicine2014;27(8):801‐6. ">Klauser 2012</a>; <a href="./references#CD001060-bbs2-0021" title="McWhorterJ , CarlanSJ , O'LearyTD . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized double‐blind trial. Obstetrics and Gynecology2002;99(4 Suppl):2S. McWhorterJ , CarlanSJ , O'LearyTD , RichichiK , O'BrienWF . Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstetrics and Gynecology2004;103:923‐30. ">McWhorter 2004</a>) changed the effect from borderline increased mortality in the magnesium sulphate group compared with controls to a non‐significant finding (RR 1.59, 95% CI 0.64 to 3.95). </p> </li> </ul> </p> </section> </section> </section> <section id="CD001060-sec-0110"> <h4 class="title">4. Magnesium sulphate for tocolysis (subgrouped by tocolytic agent)</h4> <p>None of the subgroup interaction tests indicated significant differences in effect of different tocolytic agents for the primary outcomes or for the outcomes of fetal, neonatal or infant death. See <a href="./references#CD001060-fig-0013" title="">Analysis 1.1</a>; <a href="./references#CD001060-fig-0015" title="">Analysis 1.3</a>; <a href="./references#CD001060-fig-0016" title="">Analysis 1.4</a>; <a href="./references#CD001060-fig-0021" title="">Analysis 1.9</a> for data relating to these outcomes by type of tocolytic agent. </p> </section> <section id="CD001060-sec-0111"> <h4 class="title">5. Switching/cross‐over from one tocolytic agent to another</h4> <p>Switching tocolytic agent in the event of treatment failure or adverse event was reported or suggested in 11 trials ‐ see <a href="./references#CD001060-sec-0133" title="">Characteristics of included studies</a> (but may have gone unreported in some of the other 26 trials). A sensitivity analysis omitting data for the primary outcomes and fetal/neonatal mortality from these 11 trials shows little impact for the primary outcomes of birth less than 48 hours after trial entry; serious infant composite outcome; serious maternal composite and secondary outcomes of total perinatal mortality or fetal death. However, omission of the 11 trials did shift the neonatal/infant mortality result into statistical significance (from RR 1.73, 95% CI 1.00 to 3.00 to RR 1.77, 95% CI 1.01 to 3.10). </p> <section id="CD001060-sec-0112"> <h5 class="title">Reporting bias (funnel plots)</h5> <p>We have constructed funnel plots for analyses with 10 or more trials (<a href="#CD001060-fig-0003">Figure 3</a>; <a href="#CD001060-fig-0004">Figure 4</a>; <a href="#CD001060-fig-0005">Figure 5</a>; <a href="#CD001060-fig-0006">Figure 6</a>; <a href="#CD001060-fig-0007">Figure 7</a>; <a href="#CD001060-fig-0008">Figure 8</a>; <a href="#CD001060-fig-0009">Figure 9</a>; <a href="#CD001060-fig-0010">Figure 10</a>; <a href="#CD001060-fig-0011">Figure 11</a>; <a href="#CD001060-fig-0012">Figure 12</a>). </p> <div class="figure" id="CD001060-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.1 Birth &lt; 48 hours after trial entry." data-id="CD001060-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.1 Birth &lt; 48 hours after trial entry. </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.3 Serious infant outcome." data-id="CD001060-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.3 Serious infant outcome. </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.5 Preterm birth (&lt; 37 weeks)." data-id="CD001060-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.5 Preterm birth (&lt; 37 weeks). </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.7 Gestational age at birth (weeks)." data-id="CD001060-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.7 Gestational age at birth (weeks). </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.9 Total deaths (fetal, neonatal and infant)." data-id="CD001060-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.9 Total deaths (fetal, neonatal and infant). </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.10 Fetal deaths." data-id="CD001060-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.10 Fetal deaths. </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.11 Neonatal/infant deaths." data-id="CD001060-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.11 Neonatal/infant deaths. </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.13 Respiratory distress syndrome." data-id="CD001060-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.13 Respiratory distress syndrome. </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.16 IVH (any)." data-id="CD001060-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.16 IVH (any). </p> </div> </div> </div> <div class="figure" id="CD001060-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.26 Maternal adverse effects leading to discontinuation of treatment." data-id="CD001060-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.26 Maternal adverse effects leading to discontinuation of treatment. </p> </div> </div> </div> <p>In <a href="#CD001060-fig-0008">Figure 8</a> (total deaths), there is some suggestion of asymmetry (missing small trials showing more deaths in the magnesium sulphate groups) which may be due to under‐reporting of fetal deaths. There is similar asymmetry evident for <a href="#CD001060-fig-0010">Figure 10</a> (respiratory distress syndrome) and <a href="#CD001060-fig-0011">Figure 11</a> (IVH) but none of these three instances of asymmetry are likely to be sufficient to reverse the findings of no significant differences between magnesium sulphate and control groups. </p> <p><a href="#CD001060-fig-0012">Figure 12</a> (maternal adverse effects severe enough for discontinuation) does not show a symmetrical funnel plot, perhaps due to differential influences of different tocolytic agents. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001060-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001060-sec-0113"></div> <section id="CD001060-sec-0114"> <h3 class="title" id="CD001060-sec-0114">Summary of main results</h3> <p>Given that magnesium sulphate has been widely used as a tocolytic for many years, it remains surprising that the evidence to support its use is generally unclear or with moderate to high risk of bias. </p> <p>From the available data, there was no convincing evidence of a clinically important tocolytic effect for magnesium sulphate; it did not have any substantial effect on the proportion of women delivering within 48 hours, either overall, or in any of the subgroup analyses. A higher dose did not make any difference to the outcome. Moreover, there was no evidence of any substantial improvement in neonatal morbidity. Indeed, magnesium sulphate may be associated with a borderline increase in paediatric deaths, although this result was not seen for overall fetal, neonatal and/or infant mortality or when trials with a higher risk of bias were omitted in a sensitivity analysis. Babies exposed to magnesium sulphate were not more likely to be admitted to the neonatal intensive care, but if admitted they were more likely to stay longer than those babies not exposed to magnesium sulphate. </p> <p>There was little evidence of either major benefit or harm to the mother from giving magnesium sulphate. Cessation of treatment due to maternal adverse events was not significantly different between the magnesium sulphate and control groups. </p> <p>In many comparisons there was considerable heterogeneity. Some of this may have been caused by the different drugs used in the comparison groups, ranging from betamimetics, calcium channel blockers, prostaglandin inhibitors, to nitric oxide donors. However, even in some analyses restricted to subgroups of similar tocolytics, residual heterogeneity of unknown origin remained. </p> </section> <section id="CD001060-sec-0115"> <h3 class="title" id="CD001060-sec-0115">Overall completeness and applicability of evidence</h3> <p>Some funnel plot asymmetry suggests that several small negative trials may be missing although this is unlikely to have affected the overall findings of no significant differences between magnesium sulphate and control groups. If such trials exist, they may be unpublished as a comprehensive search was done for this review. </p> <p>No long‐term outcomes were reported in any trial except for cerebral palsy in a single trial. </p> </section> <section id="CD001060-sec-0116"> <h3 class="title" id="CD001060-sec-0116">Quality of the evidence</h3> <p>Of the 37 included trials, adequate allocation concealment was reported in only six trials, mainly by the use of sealed envelopes. Four trials were quasi‐randomised. In the majority of trials magnesium sulphate was compared with other drugs with reputed tocolytic activity, which made blinding of women and investigators infeasible or very difficult. Only one trial made mention of blinding outcome assessors; and two‐thirds of trials were judged to be at some risk of selective outcome reporting bias. About one‐third of trials showed baseline imbalance in numbers randomised, probably reflecting the less than adequate randomisation in most trials. No trials were rated as being at low risk of bias on all accepted criteria. </p> </section> <section id="CD001060-sec-0117"> <h3 class="title" id="CD001060-sec-0117">Potential biases in the review process</h3> <p>Selective outcome reporting bias is likely to have been an influence in this review. Expected maternal and infant outcomes were often not reported in standard ways, such that we could not pool data for these outcomes. In particular, failure to report fetal deaths (or absence thereof) contributes to difficulty in interpreting the perinatal and infant death data. </p> </section> <section id="CD001060-sec-0118"> <h3 class="title" id="CD001060-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>The conclusions of this updated review have altered from previous versions by diluting the evidence for increased neonatal mortality when magnesium is used as a tocolytic, although findings for the primary outcomes do not differ between versions. Our findings are consistent with a recent network meta‐analysis of tocolytic therapy where prostaglandin inhibitors and calcium channel blockers (but not magnesium sulphate) showed the highest chance of delaying birth and improving neonatal and maternal outcomes (<a href="./references#CD001060-bbs2-0069" title="HaasDM , CaldwellDM , KirkparickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012</a>). The current American College of Obstetricians and Gynecology Practice Bulletin on 'Management of preterm labour' supports betamimetics, calcium channel blockers or nonsteroidal anti‐inflammatory drugs (NSAIDs) for short‐term treatment (up to 48 hours) as first‐line therapy to allow antenatal corticosteroids to be administered (<a href="./references#CD001060-bbs2-0058" title="American College of Obstetrics and Gynecology. Management of preterm labour: practice bulletin. Obstetrics &amp; Gynecology2012;119(6):1308‐16. ">ACOG 2012</a>). </p> <p>It is important to distinguish the evidence for magnesium sulphate used as a tocolytic from its use in pregnancy as an anticonvulsant (for preventing eclampsia ‐ <a href="./references#CD001060-bbs2-0065" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>) or use prior to very preterm birth for neuroprotection of the fetus and infant (<a href="./references#CD001060-bbs2-0064" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>), where short‐term use of antenatal magnesium sulphate has been shown to be effective and safe. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001060-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001060-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001060-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.1 Birth &lt; 48 hours after trial entry." data-id="CD001060-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.1 Birth &lt; 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.3 Serious infant outcome." data-id="CD001060-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.3 Serious infant outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.5 Preterm birth (&lt; 37 weeks)." data-id="CD001060-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.5 Preterm birth (&lt; 37 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.7 Gestational age at birth (weeks)." data-id="CD001060-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.7 Gestational age at birth (weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.9 Total deaths (fetal, neonatal and infant)." data-id="CD001060-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.9 Total deaths (fetal, neonatal and infant). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.10 Fetal deaths." data-id="CD001060-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.10 Fetal deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.11 Neonatal/infant deaths." data-id="CD001060-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.11 Neonatal/infant deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.13 Respiratory distress syndrome." data-id="CD001060-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.13 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.16 IVH (any)." data-id="CD001060-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.16 IVH (any). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.26 Maternal adverse effects leading to discontinuation of treatment." data-id="CD001060-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Magnesium sulphate versus comparison group ‐ all included trials, outcome: 1.26 Maternal adverse effects leading to discontinuation of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/full#CD001060-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 1 Birth &lt; 48 hours after trial entry." data-id="CD001060-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 1 Birth &lt; 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 2 Birth &lt; 24 hours after trial entry." data-id="CD001060-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 2 Birth &lt; 24 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 3 Serious infant outcome." data-id="CD001060-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 3 Serious infant outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 4 Serious maternal outcome." data-id="CD001060-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 4 Serious maternal outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 5 Preterm birth (&lt; 37 weeks)." data-id="CD001060-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 5 Preterm birth (&lt; 37 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 6 Very preterm birth (&lt; 34 weeks)." data-id="CD001060-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 6 Very preterm birth (&lt; 34 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 7 Gestational age at birth (weeks)." data-id="CD001060-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 7 Gestational age at birth (weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 8 Interval between trial entry and birth (days)." data-id="CD001060-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 8 Interval between trial entry and birth (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-09.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 9 Total deaths (fetal, neonatal and infant)." data-id="CD001060-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 9 Total deaths (fetal, neonatal and infant). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 10 Fetal deaths." data-id="CD001060-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 10 Fetal deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-11.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 11 Neonatal/infant deaths." data-id="CD001060-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 11 Neonatal/infant deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 12 Apgar &lt; 7 at 5 minutes." data-id="CD001060-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 12 Apgar &lt; 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-13.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 13 Respiratory distress syndrome." data-id="CD001060-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 13 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 14 Need for assisted ventilation." data-id="CD001060-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 14 Need for assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 15 Chronic lung disease (oxygen &gt; 28 days of age)." data-id="CD001060-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 15 Chronic lung disease (oxygen &gt; 28 days of age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-16.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 16 IVH (any)." data-id="CD001060-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 16 IVH (any). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 17 Severe IVH (Grades 3 or 4)/or PVL." data-id="CD001060-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 17 Severe IVH (Grades 3 or 4)/or PVL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 18 PVL." data-id="CD001060-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 18 PVL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 19 NEC." data-id="CD001060-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 19 NEC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 20 Proven neonatal infection (variously defined)." data-id="CD001060-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 20 Proven neonatal infection (variously defined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 21 Cerebral palsy." data-id="CD001060-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 21 Cerebral palsy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 22 Maternal death." data-id="CD001060-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 22 Maternal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 23 Cardiac arrest." data-id="CD001060-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 23 Cardiac arrest. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 24 Respiratory arrest." data-id="CD001060-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 24 Respiratory arrest. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 25 Admission to intensive care unit." data-id="CD001060-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 25 Admission to intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-26.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 26 Maternal adverse effects leading to discontinuation of treatment." data-id="CD001060-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 26 Maternal adverse effects leading to discontinuation of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 27 Nausea." data-id="CD001060-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 27 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 28 Vomiting." data-id="CD001060-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 28 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 29 Nausea and/or vomiting." data-id="CD001060-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 29 Nausea and/or vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 30 Hypotension (variously defined)." data-id="CD001060-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 30 Hypotension (variously defined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 31 Tachycardia (variously defined)." data-id="CD001060-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 31 Tachycardia (variously defined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 32 Caesarean." data-id="CD001060-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 32 Caesarean. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 33 Admission to neonatal intensive care unit." data-id="CD001060-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 33 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 34 Length of stay in neonatal intensive care unit (days)." data-id="CD001060-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Magnesium sulphate versus comparison group ‐ all included trials, Outcome 34 Length of stay in neonatal intensive care unit (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 1 Birth &lt; 48 hours after trial entry." data-id="CD001060-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 1 Birth &lt; 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 2 Serious infant outcome." data-id="CD001060-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 2 Serious infant outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 3 Serious maternal outcome." data-id="CD001060-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 3 Serious maternal outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 4 Total deaths (fetal, neonatal and infant)." data-id="CD001060-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 4 Total deaths (fetal, neonatal and infant). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 5 Fetal deaths." data-id="CD001060-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 5 Fetal deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001060-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/urn:x-wiley:14651858:media:CD001060:CD001060-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_t/tCD001060-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 6 Neonatal/infant deaths." data-id="CD001060-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Magnesium sulphate for tocolysis (subgrouped by dose), Outcome 6 Neonatal/infant deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/media/CDSR/CD001060/image_n/nCD001060-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD001060-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Magnesium sulphate versus comparison group ‐ all included trials</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth &lt; 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No alternative tocolytic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.27, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.72, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.86, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.91, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.71, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Human chorionic gonadotropin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.47, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Birth &lt; 24 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 No alternative tocolytic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.64, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.39 [1.75, 11.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.37, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious infant outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No alternative tocolytic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [0.78, 7.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.20, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.37, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.19 [0.45, 150.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.27, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Human chorionic gonadotropin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [0.69, 8.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious maternal outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 No alternative tocolytic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 HCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Preterm birth (&lt; 37 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 No alternative tocolytic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.46, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.77, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.87, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.58, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Very preterm birth (&lt; 34 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.55, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gestational age at birth (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 No other tocolytic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.85, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐1.61, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.72, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Calcium channel blockers: labour in first 48 hours subset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.93, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Calcium channel blockers: labour in 2‐10 days subset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.82, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.95, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.98, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Interval between trial entry and birth (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐3.83, 4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.72 [‐14.89, 11.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐5.06, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total deaths (fetal, neonatal and infant) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [1.00, 20.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 HCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.79 [0.93, 266.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Fetal deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [0.28, 116.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.02, 9.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 HCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Neonatal/infant deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.60, 5.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.20, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.40, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.69 [0.47, 159.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.18, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 HCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.79 [0.93, 266.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Apgar &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.39, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 No other tocolytic drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.98, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.61, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.93, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.53, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.72, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Need for assisted ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.61, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.44, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Chronic lung disease (oxygen &gt; 28 days of age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.10, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 IVH (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.34, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.13, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.65, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.37, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.37, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.46, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Severe IVH (Grades 3 or 4)/or PVL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.17, 19.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 PVL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.15, 7.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 NEC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.38, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.21, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.43, 8.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.18, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Proven neonatal infection (variously defined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.67 [0.30, 148.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.06, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.45, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.32, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Cerebral palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Various tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Cardiac arrest <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Respiratory arrest <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [0.13, 76.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Admission to intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Maternal adverse effects leading to discontinuation of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.01, 221.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.57 [0.48, 154.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.04 [0.95, 270.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5 HCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.6 Nitroglycerin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.09, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [2.29, 12.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Nitroglycerin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.82, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [0.70, 15.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.22 [2.08, 13.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 Nitroglycerin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.23, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Nausea and/or vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.31, 5.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.42 [0.44, 26.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.4 HCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>63.75 [4.01, 1013.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Hypotension (variously defined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [0.13, 76.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.5 Nitroglycerin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.14, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Tachycardia (variously defined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.04, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.04, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.03, 16.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Caesarean <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.62, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.55, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.47, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 No other tocolytic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.18, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.89, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.70, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.4 HCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.42, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Length of stay in neonatal intensive care unit (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [0.96, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 Cox inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐3.49, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3 Prostaglandin inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.40 [‐7.27, 22.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Magnesium sulphate versus comparison group ‐ all included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001060-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Magnesium sulphate for tocolysis (subgrouped by dose)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth &lt; 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Magnesium sulphate maintenance dose protocol 2 g/hour or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.60, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Magnesium sulphate maintenance dose protocol of more than 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.90, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious infant outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.81, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Magnesium sulphate maintenance dose protocol 2 g/hour or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.15, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Magnesium sulphate maintenance dose protocol of more than 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.83, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious maternal outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Magnesium sulphate maintenance dose protocol 2 g/hour or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Magnesium sulphate maintenance dose protocol of more than 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total deaths (fetal, neonatal and infant) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.39, 5.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Magnesium sulphate maintenance dose protocol 2 g/hour or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Magnesium sulphate maintenance dose protocol of more than 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.39, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fetal deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.29, 10.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Magnesium sulphate maintenance dose protocol of 2 g/hour or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Magnesium sulphate maintenance dose protocol of more than 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.29, 10.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Neonatal/infant deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.99, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Magnesium sulphate maintenance dose protocol of 2 g/hour or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.17, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Magnesium sulphate maintenance dose protocol of more than 2 g/hour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.06, 3.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Magnesium sulphate for tocolysis (subgrouped by dose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001060.pub2/references#CD001060-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001060.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001060-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001060-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001060-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001060-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001060-note-0002">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001060\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001060\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001060\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001060\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001060.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001060.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001060.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728593052"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001060.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728593056"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001060.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec8436f29f431',t:'MTc0MDcyODU5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 